COVID-19 infection and rheumatoid arthritis: Faraway, so close

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works

Clinical characteristics of coronavirus disease 2019 in China

Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016 · see citing works

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907 · see citing works

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066 · see citing works

COVID-19: consider cytokine storm syndromes and immunosuppression

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664 · see citing works

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Smolen, J. S., Landewé, R., Bijlsma, J. W. J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 7,468 · see citing works

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,967 · see citing works

Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China

Zhang, J., Dong, X., Cao, Y., Yuan, Y.-D., Yang, Y., Yan, Y., Akdiş, C. A., & Gao, Y. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004 · see citing works

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,947 · see citing works

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Smolen, J. S., Landewé, R., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A. R., van Vollenhoven, R., de Wit, M. P. T., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,753 · see citing works

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,665 · see citing works

Effective treatment of severe COVID-19 patients with tocilizumab

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,636 · see citing works

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,592 · see citing works

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475 · see citing works

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,016 · see citing works

Into the Eye of the Cytokine Storm

Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940 · see citing works

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Vincent, M. J., Bergeron, É., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,813 · see citing works

Molecular immune pathogenesis and diagnosis of COVID-19

Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.001 · Cited by 1,723 · see citing works

Coronaviruses — drug discovery and therapeutic options

Zumla, A. I., Chan, J. F., Azhar, E. I., Hui, D. S. C., & Yuen, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,689 · see citing works

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

Mulangu, S., Dodd, L. E., Davey, R. T., Mbaya, O. T., Proschan, M. A., Mukadi‐Bamuleka, D., Lusakibanza, M. M., Nzolo, D. B., Tshomba, A. O., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,617 · see citing works

On the origin and continuing evolution of SARS-CoV-2

Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Duan, Y., Zhang, H., Wang, Y., Qian, Z., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa036 · Cited by 1,592 · see citing works

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · see citing works

Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology

Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468 · see citing works

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456 · see citing works

Adult haemophagocytic syndrome

Ramos‐Casals, M., Brito‐Zerón, P., López‐Guillermo, A., Khamashta, M. A., & Bosch, X. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61048-x · Cited by 1,445 · see citing works

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Liu, C., Zhou, Q. A., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S. R., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,304 · see citing works

Middle East respiratory syndrome

Zumla, A. I., Hui, D. S. C., & Perlman, S. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,280 · see citing works

SARS: systematic review of treatment effects

Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217 · see citing works

Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study

Doran, M. F., Crowson, C. S., Pond, G. R., O’Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10524 · Cited by 1,213 · see citing works

Interferons at age 50: past, current and future impact on biomedicine

Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154 · see citing works

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Arabi, Y. M., Mandourah, Y., Al-Hameed, F. M., Sindi, A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R. L., Al‐Omari, A., Kharaba, A. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122 · see citing works

COVID-19: combining antiviral and anti-inflammatory treatments

Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117 · see citing works

A human monoclonal antibody blocking SARS-CoV-2 infection

Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F. G., & Bosch, B. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,115 · see citing works

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Devaux, C. A., Rolain, J., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,099 · see citing works

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

Boers, M., Verhoeven, A. C., Markusse, H. M., van de Laar, M. A., Westhovens, R., van Denderen, J. C., van Zeben, D., Dijkmans, B. A. C., Peeters, A. J., Jacobs, P., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01300-7 · Cited by 1,073 · see citing works

Kinase inhibitors: the road ahead

Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009 · see citing works

RNAi-Mediated Chromatin Silencing in Fission Yeast

White, S. A., & Allshire, R. C. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-75157-1_8 · Cited by 971 · see citing works

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Singh, J. A., Wells, G., Christensen, R., Tanjong-Ghogomu, E., Maxwell, L. J., Macdonald, J., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 966 · see citing works

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867 · see citing works

Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2

Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., & Zuo, W. (2020) · doi:10.1101/2020.01.26.919985 · Cited by 860 · see citing works

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

Dougados, M., Soubrier, M., Antunez, A., Balint, P. V., Balsa, A., Buch, M. H., Casado, G. C., Detert, J., Elzorkany, B. K., Emery, P., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204223 · Cited by 856 · see citing works

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

Ramiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M. H., Gossec, L., van der Heijde, D. M. F. M., Winthrop, K. L., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204575 · Cited by 701 · see citing works

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

Galloway, J. B., Hyrich, K. L., Mercer, L., Dixon, W. G., Fu, B., Ustianowski, A., Watson, K. D., Lunt, M., Symmons, D. P. M., & on behalf of the British Society for Rheumatology Biologics Register (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq242 · Cited by 678 · see citing works

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Keyaerts, E., Vijgen, L., Maes, P., Neyts, J. H., & Ranst, M. A. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 644 · see citing works

Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

Lim, J., Jeon, S., Shin, H., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K. W., Kang, Y. M., Lee, B., & Park, S.-J. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e79 · Cited by 637 · see citing works

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

Singh, J. A., Cameron, C. G., Noorbaloochi, S., Cullis, T., Tucker, M. D., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 624 · see citing works

The emerging safety profile of JAK inhibitors in rheumatic disease

Winthrop, K. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 583 · see citing works

New insights into the antiviral effects of chloroquine

Savarino, A., Trani, L. D., Donatelli, I., Cauda, R., & Cassone, A. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70361-9 · Cited by 570 · see citing works

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562 · see citing works

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541 · see citing works

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Sanchez, G. A. M., Reinhardt, A., RAMSEY, S. E., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murías, S., Dare, J. A., Brown, D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98814 · Cited by 537 · see citing works

Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry

Haga, S., Yamamoto, N., Nakai-Murakami, C., Osawa, Y., Tokunaga, K., Sata, T., Yamamoto, N., Sasazuki, T., & Ishizaka, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711241105 · Cited by 522 · see citing works

Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

van Everdingen, A. A., Jacobs, J. W. G., van Reesema, D. R. S., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 488 · see citing works

Middle East respiratory syndrome

Memish, Z. A., Perlman, S. M., Kerkhove, M. D. V., & Zumla, A. I. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33221-0 · Cited by 481 · see citing works

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

Zou, Z., Yan, Y., Shu, Y., Gao, R., Sun, Y., Li, X., Ju, X., Liang, Z., Liu, Q., Zhao, Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms4594 · Cited by 401 · see citing works

Comorbidities in rheumatoid arthritis

Michaud, K. D., & Wolfe, F. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.06.002 · Cited by 400 · see citing works

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Ni, Y.-N., Chen, G., Sun, J., Liang, B., & Liang, Z.-A. (2019) · Critical Care · doi:10.1186/s13054-019-2395-8 · Cited by 392 · see citing works

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)Preprint

Diao, B., Wang, C., Tan, Y., et al. (2020) · medRxiv · doi:10.1101/2020.02.18.20024364 · Cited by 366 · see citing works

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Ramiro, S., Sepriano, A. R., Chatzidionysiou, K., Nam, J. L., Smolen, J. S., van der Heijde, D. M. F. M., Dougados, M., van Vollenhoven, R., Bijlsma, J. W. J., Burmester, G. R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210708 · Cited by 358 · see citing works

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R. D., Krishnaswami, S., Kawabata, T. T., & Riese, R. J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 355 · see citing works

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis

Au, K., Reed, G. W., Curtis, J. R., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.128637 · Cited by 340 · see citing works

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

Bakker, M. F., Jacobs, J. W. G., Welsing, P. M. J., Verstappen, S. M. M., Tekstra, J., Ton, E., Geurts, M. A. W., van der Werf, J. H., van Albada-Kuipers, G. A., Veen, Z. N. J.-D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-5-201203060-00004 · Cited by 322 · see citing works

Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System

Strehl, C., Ehlers, L., Gaber, T., & Buttgereit, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01744 · Cited by 308 · see citing works

A human monoclonal antibody blocking SARS-CoV-2 infectionPreprint

Wang, C., Li, W., Drabek, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.987958 · Cited by 289 · see citing works

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285 · see citing works

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 284 · see citing works

The risk of hospitalized infection in patients with rheumatoid arthritis.

Smitten, A. L., Choi, H. K., Hochberg, M. C., et al. (2008) · PubMed · Cited by 278 · see citing works

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Sepriano, A. R., Kerschbaumer, A., Smolen, J. S., van der Heijde, D. M. F. M., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W. J., Burmester, G. R., de Wit, M. P. T., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216653 · Cited by 277 · see citing works

JAK inhibitors for the treatment of autoimmune and inflammatory diseases

Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264 · see citing works

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T. P., Chen, L., Dickson, C. L., Camp, J. R., Cardillo, T. E., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.171361 · Cited by 258 · see citing works

Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway

Wang, W., Ye, L., Li, Y., Li, B., Gao, B., Zeng, Y., Kong, L., Fang, X., Zheng, H., Wu, Z., et al. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.007 · Cited by 247 · see citing works

Early Enhanced Expression of Interferon-Inducible Protein-10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute Respiratory Syndrome

Tang, N. L. S., Chan, P. K. S., Wong, C.-K., To, K., Wu, A. K. L., Sung, Y.-M., Hui, D. S. C., Sung, J. J. �., & Lam, C. W. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.054460 · Cited by 231 · see citing works

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Bekerman, E., Neveu, G., Shulla, A., Brannan, J. M., Pu, S., Wang, S., Xiao, F., Barouch‐Bentov, R., Bakken, R. R., Mateo, R., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89857 · Cited by 231 · see citing works

Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis

Widdifield, J., Bernatsky, S., Paterson, J. M., Gunraj, N., Thorne, J. C., Pope, J., Cividino, A., & Bombardier, C. (2013) · Arthritis Care & Research · doi:10.1002/acr.21812 · Cited by 219 · see citing works

Challenges in the treatment of Rheumatoid Arthritis

Conigliaro, P., Triggianese, P., Martino, E. D., Fonti, G. L., Chimenti, M. S., Sunzini, F., Viola, A., Canofari, C., & Perricone, R. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.05.007 · Cited by 210 · see citing works

Pharmacological agents for adults with acute respiratory distress syndrome

Lewis, S. R., Pritchard, M., Thomas, C., & Smith, A. F. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004477.pub3 · Cited by 198 · see citing works

Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics

Wang, W., Liu, X., Wu, S.-P., Chen, S., Li, Y., Nong, L., Lie, P., Huang, L., Cheng, L., Lin, Y., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa387 · Cited by 193 · see citing works

The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses

Dixon, W. G., Suissa, S., & Hudson, M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3453 · Cited by 191 · see citing works

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

Paton, N. I., Lee, L., Xu, Y., Ooi, E. E., Cheung, Y. B., Archuleta, S., Wong, G., & Smith, A. W. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70065-2 · Cited by 189 · see citing works

Use of nonbiologic disease‐modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

Lacaille, D. V., Guh, D. P., Abrahamowicz, M., Anis, A. H., & Esdaile, J. M. (2008) · Arthritis Care & Research · doi:10.1002/art.23913 · Cited by 188 · see citing works

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

Atzeni, F., Sarzi‐Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E. G., Frati, E. R., Foschi, V., Gasparini, S., Giardina, A. R., et al. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.06.008 · Cited by 169 · see citing works

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rutherford, A. I., Subesinghe, S., Hyrich, K. L., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212825 · Cited by 167 · see citing works

Influenza Virus Non-Structural Protein 1 (NS1) Disrupts Interferon Signaling

Jia, D., Rahbar, R., Chan, R. W. Y., Lee, S. M. Y., Chan, M. C. W., Wang, B. X., Baker, D. P., Sun, B., Peiris, M. J. S., Nicholls, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013927 · Cited by 166 · see citing works

Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis

Franklin, J., Lunt, M., Bunn, D. K., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057265 · Cited by 160 · see citing works

Serious infections during anti-TNFα treatment in rheumatoid arthritis patients

Favalli, E. G., Desiati, F., Atzeni, F., et al. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.11.002 · Cited by 151 · see citing works

Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis

Seguin, A., Galicier, L., Boutboul, D., Lemiale, V., & Azoulay, É. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.11.004 · Cited by 151 · see citing works

Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection

Roques, P., Thiberville, S.-D., Dupuis-Maguiraga, L., Lum, F., Labadie, K., Martinon, F., Gras, G. S., Lebon, P., Ng, L. F. P., de Lamballerie, X. N., et al. (2018) · Viruses · doi:10.3390/v10050268 · Cited by 149 · see citing works

The NS1 Protein: A Multitasking Virulence Factor

Ayllón, J., & García‐Sastre, A. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_400 · Cited by 148 · see citing works

Family-wide Structural Analysis of Human Numb-Associated Protein Kinases

Sorrell, F. J., Szklarz, M., Azeez, K. R. A., et al. (2016) · Structure · doi:10.1016/j.str.2015.12.015 · Cited by 142 · see citing works

Ibuprofen Attenuates Cardiac Fibrosis in Streptozotocin-Induced Diabetic Rats

Qiao, W., Wang, C., Chen, B., Zhang, F., Liu, Y., Lü, Q., Guo, H., Yan, C., Sun, H. B., Hu, G., et al. (2015) · Cardiology · doi:10.1159/000375362 · Cited by 137 · see citing works

Respiratory viral infections and the risk of rheumatoid arthritis

Joo, Y. B., Lim, Y.-H., Kim, K., Park, K., & Park, Y. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1977-9 · Cited by 136 · see citing works

Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis

Ranganath, V. K., Maranian, P., Elashoff, D. A., et al. (2013) · Lara D. Veeken · doi:10.1093/rheumatology/ket224 · Cited by 122 · see citing works

Comparison of the Antiviral Activity in vitro of some Non-steroidal Anti-inflammatory Drugs

Inglot, A. D. (1969) · Journal of General Virology · doi:10.1099/0022-1317-4-2-203 · Cited by 121 · see citing works

Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists

Fleming, S. B. (2016) · Vaccines · doi:10.3390/vaccines4030023 · Cited by 120 · see citing works

Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

Widjaja, I., Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., van Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado, R., Grosveld, F., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1597644 · Cited by 115 · see citing works

Infectome: A platform to trace infectious triggers of autoimmunity

Bogdanos, D. P., Smyk, D. S., Invernizzi, P., Rigopoulou, E. I., Blank, M., Pouria, S., & Shoenfeld, Y. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.12.005 · Cited by 109 · see citing works

Middle East Respiratory Syndrome

Shalhoub, S., Memish, Z. A., & Arabi, Y. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-54841-0.00004-4 · Cited by 108 · see citing works

Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment

Pu, S., Xiao, F., Schor, S., Bekerman, E., Zanini, F., Barouch‐Bentov, R., Nagamine, C. M., & Einav, S. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.05.001 · Cited by 106 · see citing works

Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis

Ibrahim, A., Ahmed, M., Conway, R. P., & CAREY, J. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010015 · Cited by 102 · see citing works

Infections and arthritis

Mathew, A. J., & Ravindran, V. K. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.04.009 · Cited by 98 · see citing works

The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives

Favalli, E. G., Raimondo, M. G., Becciolini, A., Crotti, C., Biggioggero, M., & Caporali, R. F. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.002 · Cited by 94 · see citing works

AB0156 Thymic stromal lymphopoietin (TSLP) in primary sjÖgren's syndrome and related lymphoma: the possible contribution of a novel growth factor

Gandolfo, S., Fabro, C., Bulfoni, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.6450 · Cited by 88 · see citing works

Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an “anchor” drug?

Favalli, E. G., Biggioggero, M., & Meroni, P. L. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.026 · Cited by 87 · see citing works

Adult haemophagocytic lymphohistiocytosis: a review

Yıldız, H., Neste, E. V. D., Defour, J., Danse, E. M., & Yombi, J. C. (2020) · QJM · doi:10.1093/qjmed/hcaa011 · Cited by 75 · see citing works

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Biggioggero, M., Becciolini, A., Crotti, C., & Agape, E. (2019) · Drugs in Context · doi:10.7573/dic.212595 · Cited by 72 · see citing works

Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study

Pawar, A. M., Desai, R. J., Gautam, N., & Kim, S. C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30137-7 · Cited by 65 · see citing works

Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders

Tudesq, J., Cartron, G., Rivière, S., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.015 · Cited by 63 · see citing works

Real-world experience with tofacitinib for the treatment of rheumatoid arthritis.

Caporali, R. F., & Zavaglia, D. (2019) · PubMed · Cited by 60 · see citing works

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis

Accortt, N. A., Lesperance, T., Liu, M., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23426 · Cited by 58 · see citing works

Erratum: Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response

Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P. D., & Rice, C. M. (2015) · Nature · doi:10.1038/nature14554 · Cited by 44 · see citing works

Long-term safety of abatacept in patients with rheumatoid arthritis

Atzeni, F., Sarzi‐Puttini, P., Mutti, A., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.06.011 · Cited by 33 · see citing works

Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

Bello, S. L., Serafino, L., Bonali, C., et al. (2012) · Reumatismo · doi:10.4081/reumatismo.2012.299 · Cited by 28 · see citing works

Review: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective

Shale, M., Czub, M., Kaplan, G. G., Panaccione, R., & Ghosh, S. K. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10366368 · Cited by 24 · see citing works

Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at Onset: Results from a longitudinal cohort study of tatarstan women

Arleevskaya, M. I., Shafigullina, A. Z., Filina, Y. V., Lemerle, J., & Renaudineau, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01725 · Cited by 24 · see citing works

The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis

Favalli, E. G., Matucci‐Cerinic, M., & Szekanecz, Z. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102421 · Cited by 18 · see citing works

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

Jacobs, J. W. G., Bakker, M. F., & Bijlsma, J. W. J. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00020 · Cited by 14 · see citing works

Tofacitinib's infectious profile: concerns for clinical practice

Favalli, E. G. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30001-1 · Cited by 10 · see citing works

Can we wean patients with inflammatory arthritis from biological therapies?

Edwards, C. J., Galeazzi, M., Bellinvia, S., et al. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102399 · Cited by 6 · see citing works

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654 · see citing works

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192 · see citing works

Viral Infections, the Microbiome, and Probiotics

Harper, A., Vijayakumar, V., Ouwehand, A. C., ter Haar, J., Obis, D., Espadaler, J., Binda, S., Desiraju, S., & Day, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.596166 · Cited by 177 · see citing works

Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study

Rodriguez-Garcia, J. L., Sanchez-Nievas, G., Arevalo-Serrano, J., Garcia-Gomez, C., Jimenez-Vizuete, J. M., & Martinez-Alfaro, E. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa587 · Cited by 112 · see citing works

The overall impact of <scp>COVID</scp> ‐19 on healthcare during the pandemic: A multidisciplinary point of view

Sabetkish, N., & Rahmani, A. (2021) · Health Science Reports · doi:10.1002/hsr2.386 · Cited by 68 · see citing works

Tocilizumab for treating juvenile idiopathic arthritis

Turnier, J. L., & Brunner, H. I. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1150997 · Cited by 27 · see citing works

Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2

Barkas, F., Liontos, A., Svarna, E., et al. (2020) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000375

OA31 Real life experience of tocilizumab treatment for giant cell arteritis

Hutton, L. M. M. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead104.031 · Cited by 1 · see citing works

Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease

Rida-e-Zehra, S., Kausar, S., Latif, A., et al. (2021) · International Journal of Infectious Diseases and Therapy · doi:10.11648/j.ijidt.20210601.15

Therapeutic effect of tocilizumab on inhibiting cytokine release syndrome in severe Coronavirus Disease 2019 patients

Xi, H., Mao, Y., Xu, L., et al. (2022) · Integrative Medicine in Nephrology and Andrology · doi:10.4103/2773-0387.346051